Meeting
2022 ASCO Gastrointestinal Cancers Symposium
A randomized phase II trial of preoperative chemotherapy of S-1/CDDP with or without trastuzumab followed by surgery in HER2 positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study).
Authors
Masanori Tokunaga
Gastrointestinal Surgery, Tokyo Medical and Dental University, Bunkyo-Ku, Tokyo, Japan
Masanori Tokunaga , Nozomu Machida , Junki Mizusawa , Hiroshi Yabusaki , Hirofumi Yasui , Motohiro Hirao , Masaya Watanabe , Takushi Yasuda , Takahiro Kinoshita , Hiroshi Imamura , Jun Hihara , Narikazu Boku , Tomoko Kataoka , Takaki Yoshikawa , Takeshi Sano , Mitsuru Sasako , Masanori Terashima
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
UMIN000016920
DOI
10.1200/JCO.2022.40.4_suppl.285
Abstract #
285
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A randomized phase II trial of systemic chemotherapy with or without trastuzumab followed by surgery in HER2 positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger study).
First Author: Masanori Tokunaga
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase II study of perioperative capecitabine plus oxaliplatin (CapeOx) therapy for advanced gastric cancer with multiple lymph node metastases (OGSG 1701).
First Author: Shunji Endo
Poster
2018 Gastrointestinal Cancers Symposium
A phase II trial of first-line FOLFIRINOX for patients with advanced gastroesophageal adenocarcinoma.
First Author: Haeseong Park
Poster
2017 ASCO Annual Meeting
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: Petrarca—A phase II trial of the German AIO.
First Author: Ralf Hofheinz